Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KOD Stock Forecast 2026-2027
$40.41
Current Price
$2.77B
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to KOD Price Targets
+98.0%
To High Target of $80.00
+46.0%
To Median Target of $59.00
-65.4%
To Low Target of $14.00
KOD Price Momentum
-6.3%
1 Week Change
+83.0%
1 Month Change
+1,322.9%
1 Year Change
+44.5%
Year-to-Date Change
-13.4%
From 52W High of $46.67
+1,762.2%
From 52W Low of $2.17
📊 TOP ANALYST CALLS
Did KOD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Kodiak is one of their latest high-conviction picks.
Latest KOD Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, KOD has a bullish consensus with a median price target of $59.00 (ranging from $14.00 to $80.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $40.41, the median forecast implies a 46.0% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Yee at UBS, projecting a 98.0% upside. Conversely, the most conservative target is provided by Daniil Gataulin at Chardan Capital, suggesting a 65.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KOD Analyst Ratings
6
Buy
1
Hold
0
Sell
KOD Price Target Range
Low
$14.00
Average
$59.00
High
$80.00
Current: $40.41
Latest KOD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KOD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 27, 2026 | UBS | Michael Yee | Buy | Maintains | $80.00 |
| Mar 27, 2026 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $58.00 |
| Feb 10, 2026 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $38.00 |
| Jan 22, 2026 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $38.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Initiates | $50.00 |
| Nov 17, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $26.00 |
| Nov 17, 2025 | Chardan Capital | Daniil Gataulin | Neutral | Maintains | $14.00 |
| Nov 11, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Upgrade | $24.00 |
| Oct 24, 2025 | JP Morgan | Anupam Rama | Overweight | Upgrade | $24.00 |
| Oct 23, 2025 | LifeSci Capital | Patrick Dolezal | Outperform | Initiates | $40.00 |
| Oct 6, 2025 | Chardan Capital | Daniil Gataulin | Neutral | Maintains | $14.00 |
| Sep 25, 2025 | Barclays | Gena Wang | Equal-Weight | Upgrade | $17.00 |
| Sep 22, 2025 | Jefferies | Maury Raycroft | Buy | Initiates | $15.00 |
| Aug 18, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Maintains | $5.00 |
| Aug 14, 2025 | JP Morgan | Anupam Rama | Neutral | Upgrade | $15.00 |
| Aug 14, 2025 | Barclays | Gena Wang | Underweight | Maintains | $7.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $3.00 |
| Dec 9, 2024 | Jefferies | Michael Yee | Buy | Upgrade | $20.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $3.00 |
| Nov 15, 2024 | Barclays | Gena Wang | Underweight | Maintains | $4.00 |
Kodiak Sciences Inc. (KOD) Competitors
The following stocks are similar to Kodiak based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kodiak Sciences Inc. (KOD) Financial Data
Kodiak Sciences Inc. has a market capitalization of $2.77B with a P/E ratio of -10.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -149.5%.
Valuation Metrics
Market Cap
$2.77B
Enterprise Value
$2.34B
P/E Ratio
-10.4x
PEG Ratio
-0.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+8.4%
Current Ratio
4.7x
Debt/Equity
37.6x
ROE
-149.5%
ROA
-42.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Kodiak Sciences Inc. (KOD) Business Model
About Kodiak Sciences Inc.
What They Do
Develops therapeutics for retinal diseases.
Business Model
Kodiak Sciences Inc. operates as a clinical-stage biopharmaceutical company focusing on the research and development of novel therapies for chronic retinal diseases. The company generates revenue through the advancement and potential commercialization of its proprietary drug candidates, which target prevalent ophthalmic conditions leading to vision loss.
Additional Information
Headquartered in Palo Alto, California, and founded in 2009, Kodiak Sciences is advancing its key pipeline candidates, including KSI-301 in Phase 3 studies, KSI-501 for inflammatory conditions, and KSI-101 targeting retinal inflammation. The company aims to address significant unmet needs in ophthalmology through its innovative Antibody Biopolymer Conjugate Drug platform.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
123
CEO
Dr. Victor Perlroth M.D.
Country
United States
IPO Year
2018
Website
kodiak.comKodiak Sciences Inc. (KOD) Latest News & Analysis
Latest News
Kodiak Sciences: Road To $120
18 days ago
Quick Summary
Kodiak Sciences (NASDAQ: KOD) surged 62% last week to $37, raising its market cap to $2.3 billion, following positive Phase 3 GLOW2 results for its treatment Zenkuda.
Why It Matters
Kodiak Sciences' 62% stock surge reflects strong investor confidence following positive Phase 3 results for Zenkuda, potentially enhancing future revenue and growth prospects.
Source: Forbes
Market Sentiment:
Positive
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
17 days ago
Quick Summary
Kodiak Sciences Inc. (Nasdaq: KOD) announced its fourth-quarter and full-year financial results for 2025, along with recent business highlights, on March 31, 2026.
Why It Matters
Kodiak Sciences' Q4 and full-year financial results can impact stock performance, influencing investor sentiment and future valuation based on growth potential and financial health.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
KOD reported a larger Q4 loss, but its pipeline is progressing, highlighted by positive phase III data for Zenkuda, leading to expedited regulatory plans.
Why It Matters
Wider Q4 losses may raise concerns, but positive phase III data for Zenkuda and accelerated regulatory plans suggest potential for future revenue growth, impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Investors are reacting positively to strong data and the potential for an accelerated biologics license application (BLA).
Why It Matters
Strong data and a quicker route to a biologics license application can enhance a company's market potential and valuation, prompting positive investor sentiment and potential stock price increases.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Kodiak Sciences shares surged 75% following positive phase III GLOW2 trial results for Zenkuda, demonstrating strong efficacy and safety in diabetic retinopathy patients.
Why It Matters
Kodiak Sciences' 75% rally reflects strong phase III trial results for Zenkuda, indicating potential market success and profitability, which can significantly impact investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Kodiak Sciences' shares rose 52% after its experimental drug successfully met key objectives in a late-stage study for diabetes-related eye damage.
Why It Matters
Kodiak Sciences' 52% pre-market share surge indicates strong investor confidence due to positive trial results, suggesting potential for significant revenue growth and market impact.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About KOD Stock
What is Kodiak Sciences Inc.'s (KOD) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Kodiak Sciences Inc. (KOD) has a median price target of $59.00. The highest price target is $80.00 and the lowest is $14.00.
Is KOD stock a good investment in 2026?
According to current analyst ratings, KOD has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $40.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KOD stock?
Wall Street analysts predict KOD stock could reach $59.00 in the next 12 months. This represents a 46.0% increase from the current price of $40.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kodiak Sciences Inc.'s business model?
Kodiak Sciences Inc. operates as a clinical-stage biopharmaceutical company focusing on the research and development of novel therapies for chronic retinal diseases. The company generates revenue through the advancement and potential commercialization of its proprietary drug candidates, which target prevalent ophthalmic conditions leading to vision loss.
What is the highest forecasted price for KOD Kodiak Sciences Inc.?
The highest price target for KOD is $80.00 from Michael Yee at UBS, which represents a 98.0% increase from the current price of $40.41.
What is the lowest forecasted price for KOD Kodiak Sciences Inc.?
The lowest price target for KOD is $14.00 from Daniil Gataulin at Chardan Capital, which represents a -65.4% decrease from the current price of $40.41.
What is the overall KOD consensus from analysts for Kodiak Sciences Inc.?
The overall analyst consensus for KOD is bullish. Out of 16 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $59.00.
How accurate are KOD stock price projections?
Stock price projections, including those for Kodiak Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 9:39 PM UTC